Suppr超能文献

新型抗真菌药物K-582对实验性念珠菌性角膜炎的作用

The effect of K-582, a new antifungal agent, on experimental Candida keratitis.

作者信息

Ohno S, Fuerst D J, Okumoto M, Grabner G, Smolin G

出版信息

Invest Ophthalmol Vis Sci. 1983 Dec;24(12):1626-9.

PMID:6360948
Abstract

K-582, a new basic peptide antibiotic, was tested in rabbits with experimental Candida keratitis. It was shown that the K-582-treated group showed statistically highly significant therapeutic effects on days 2 and 3, as compared with the control group (day 2: P less than 0.001; day 3: P less than 0.001). The culture study showed that the average number of colonies was 1,573.1 in the controls and 463.3 in the treated group, and the difference was highly significant statistically (P less than 0.001). No ocular or systemic toxic effects were observed with this drug. K-582 is a promising new drug for the treatment of Candida keratitis.

摘要

新型碱性肽抗生素K-582在患有实验性念珠菌性角膜炎的兔子身上进行了测试。结果显示,与对照组相比,K-582治疗组在第2天和第3天显示出具有统计学意义的高度显著治疗效果(第2天:P<0.001;第3天:P<0.001)。培养研究表明,对照组的平均菌落数为1573.1,治疗组为463.3,差异具有高度统计学意义(P<0.001)。未观察到该药物有眼部或全身毒性作用。K-582是一种有前景的治疗念珠菌性角膜炎的新药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验